Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluguard versus Vaxigrip quadrivalent seasonal influenza vaccine immunogenicity and safety study
IRCT20200318046812N4Phase 3Completed
- Sponsor
- Nivad Pharmed Salamat
- Start
- Jan 2021
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in influenza comparing Fluguard with Vaxigrip (2 arms). Primary endpoint: Geometric mean titer ratio at Day 28 for influenza strains. Started Jan 2021; status: completed.
02
Drugs
favipiravirinfluenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on IRCT20200318046812N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200318046812N4.